Try our beta test site

ALS Reversals - Lunasin Regimen

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Richard Bedlack, M.D., Ph.D., Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT02709330
First received: March 5, 2016
Last updated: February 6, 2017
Last verified: February 2017
  Purpose
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group. Participants will receive a Lunasin regimen and will be asked to register for an account of PatientsLikeMe website, where after the initial in-clinic visit, they will be asked to enter specific data.

Condition Intervention Phase
ALS (Amyotrophic Lateral Sclerosis)
Drug: Lunasin Regimen
Other: Historical control
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-label, Single-center, 12-month Trial of a Lunasin Regimen for Patients With Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Change in Revised ALS Functional Rating Scale (ALSFRS-R) [ Time Frame: Screening/baseline - 12 months ]

Secondary Outcome Measures:
  • Change in histone acetylation [ Time Frame: Screening/baseline, Month 1 ]
  • Percent agreement between the weights obtained by patients and study coordinator [ Time Frame: Month 1, Month 12 ]
    To confirm that participants can accurately measure their own weight, even as they become more disabled by ALS, the investigators will compare the participant-generated weight with the weight obtained by the study coordinator at the Month 1 and Month 12 visits. A simple description of the accuracy (percent agreement between the weights) will be used.

  • Enrollment rate [ Time Frame: Screening/baseline - Month 12 ]
  • Retention rate [ Time Frame: Month 12 ]
  • Frequency of ALS reversals [ Time Frame: Screening/baseline - Month 12 ]
  • ALSFRS-R Accuracy [ Time Frame: Month 1 ]
    To confirm that participants can accurately measure their own ALS Functional Rating Scale (Revised, ALSFRS-R), the investigators will compare the ALSFRS-R obtained by the coordinator with that obtained by the participants themselves at the Month 1 Visit. Correlational analysis between these 2 scores will be performed with Spearman's rho.


Enrollment: 50
Actual Study Start Date: April 2016
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lunasin regimen

The Lunasin regimen consists of:

  • LunaRich X Capsules (12 capsules per day)
  • Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)
  • Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)

It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate.

Drug: Lunasin Regimen
LunaRich X Capsules, Reliv Now, ProVantage
Active Comparator: Historical controls
For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
Other: Historical control
Matched historical controls will be identified from the PatientsLikeMe database.

Detailed Description:

The primary hypothesis is that a supplement regimen containing Lunasin (referred to as the Lunasin regimen) can decrease the rate of ALSFRS-S progression by 50% relative to matched historic controls.

ALS is a devastating motor neuron disease that causes rapidly progressive muscle weakness, disability and premature death. In spite of a large number of attempted ALS trials, there are no significant disease-modifying therapies for this condition.

It was recently reported that a patient with a validated diagnosis of ALS, had experienced dramatic objective improvement in speech, swallowing and limb strength while taking a supplement regimen containing Lunasin. Several other patients with ALS have also reported improvement on this Lunasin regiment, though records were not obtainable to validate these.

The Lunasin regimen will consist of:

  • LunaRich X Capsules
  • Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants'
  • Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids'

Dosages will be titrated up to target over the first 6 days. The subject will take the highest tolerated dosing for the remainder of the 12-month study.

There are 3 in-clinic visits which occur at screening/baseline, Month 1 and Month 12. For Months 2-11, participants will make "virtual visits" by measuring their own ALSFRS-R score and weight and will record it in the PatientsLikeMe website. They will also self-report any perceived efficacy, compliance, adverse events and changes in concomitant medications.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, aged at least 18 years.
  • Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
  • Patient is able to understand and express informed consent (in the opinion of the site investigator).
  • Patient has access to the Internet on a desktop computer, laptop, or tablet and has a working email address.
  • Patient or caregiver is willing and able to use a computer and enter data on a secure website.
  • Patient is able to read and write English.
  • Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.

Exclusion Criteria:

  • Patient is taking other experimental treatments for ALS.
  • Prior side effects from Lunasin.
  • Known soy allergy.
  • Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study.
  • Pregnant women or women currently breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02709330

Locations
United States, North Carolina
Duke Medicine / Neurology
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Richard Bedlack, M.D., Ph.D.
Investigators
Principal Investigator: Richard Bedlack, M.D., Ph.D. Associate Professor of Neurology
  More Information

Responsible Party: Richard Bedlack, M.D., Ph.D., Associate Professor of Neurology, Duke University Medical Center
ClinicalTrials.gov Identifier: NCT02709330     History of Changes
Other Study ID Numbers: Pro00063754 
Study First Received: March 5, 2016
Last Updated: February 6, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Participants will be assigned a global unique ID number (GUID), which will allow de-identified data sharing.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases

ClinicalTrials.gov processed this record on February 20, 2017